Search Results
ESA and other growth factors for MDS
Erythropoiesis Stimulating Agents and other Growth Factors in Low-risk MDS: An update
Debate: Hypomethylating agents are appropriate in lower-risk MDS - Only Use With Caution
Options in Low-Risk Disease MDS
The impact of ESAs in lower-risk MDS
MDS - Myeloplastic Syndromes - 2023 Best of Hematology Conference
Lower-risk MDS in 2021: luspatercept, imetelstat & roxadustat
Understanding Higher Risk MDS and Transtion to AML
ESAs for the management of lower-risk MDS
Updates from the 17th International Congress on MDS: Promising Treatment Advances
MDS: Factors to Consider in the Initial Treatment Approach
What are erythropoietin-stimulating agents (ESAs)?
